Zobrazeno 1 - 10
of 12 072
pro vyhledávání: '"Population pharmacokinetics"'
Autor:
Takuya Azechi, Yutaka Fukaya, Chika Nitani, Junichi Hara, Hiroshi Kawamoto, Tomoaki Taguchi, Kenichi Yoshimura, Akihiro Sato, Naoko Hattori, Toshikazu Ushijima, Toshimi Kimura
Publikováno v:
Current Oncology, Vol 31, Iss 11, Pp 7155-7164 (2024)
Tamibarotene is a synthetic retinoid that inhibits tumor cell proliferation and promotes differentiation. We previously reported on the safety and tolerability of tamibarotene in patients with recurrent or refractory solid tumors. Therefore, in this
Externí odkaz:
https://doaj.org/article/6673ca9bbc854ff79924f0043a2c1b6f
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 12, Pp 2617-2635 (2024)
Abstract Introduction This study characterized the population pharmacokinetics (PK) of vancomycin in patients treated with and without continuous renal replacement therapy (CRRT) or temporary mechanical circulatory support (tMCS), including extracorp
Externí odkaz:
https://doaj.org/article/7fd99f6cdfca49d3ba27a2a9e4a18368
Autor:
Pan Ma, Huan Ma, Ruixiang Liu, Haini Wen, Haisheng Li, Yifan Huang, Ying Li, Lirong Xiong, Linli Xie, Qian Wang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract The pharmacokinetics of vancomycin exhibit significant inter-individual variability, particularly among elderly patients. This study aims to develop a predictive model that integrates machine learning with population pharmacokinetics (popPK)
Externí odkaz:
https://doaj.org/article/e03f7f3f82924739b2076f61bbf834be
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Objective This study aimed to develop a population pharmacokinetic (PPK) model for oral apatinib in Chinese oncology patients and investigate the factors influencing the pharmacokinetics of apatinib. Methods We gathered 199 blood concentrati
Externí odkaz:
https://doaj.org/article/1e9096f01ffd4f5b9f7365060cb85dfe
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 4459-4469 (2024)
Shuping Song,1,* Jieqiong Liu,2,3,* Wei Su,1 Haitao Yu,4 Binbin Feng,1 Yinshan Wu,1 Feng Guo,1 Zhenwei Yu2 1Intensive Care Unit, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 2Depa
Externí odkaz:
https://doaj.org/article/ec2e7c546d254513b72ded7b8865bc18
Autor:
Hardik Chandasana, Sven C. van Dijkman, Rashmi Mehta, Mark Bush, Helena Rabie, Patricia Flynn, Tim R. Cressey, Edward P. Acosta, Kristina M. Brooks, for the IMPAACT 2019 Study Team
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 8, Pp 1877-1891 (2024)
Abstract Introduction Once-daily fixed-dose combinations (FDC) containing abacavir (ABC), dolutegravir (DTG), and lamivudine (3TC) have been approved in the US for adults and children with HIV weighing ≥ 6 kg. This analysis assessed the ability of
Externí odkaz:
https://doaj.org/article/e73069ec1f6d483aaaca734cc3350bf7
Autor:
Rančić Aleksandar, Milosavljević Miloš N., Rosić Nikola, Milovanović Dragan, Folić Marko, Zečević Dejana Ružić, Petrović Nemanja, Čorbić Mirjana Milojević, Dabanović Vera, Janković Slobodan M.
Publikováno v:
Open Medicine, Vol 19, Iss 1, Pp 803-38 (2024)
The pharmacokinetics of meropenem are significantly altered in critically ill patients. A population pharmacokinetic study was designed to estimate typical values of meropenem clearance in critically ill patients and evaluate potential factors of inf
Externí odkaz:
https://doaj.org/article/f65fa220b750478396a1ca7e70102a14
Autor:
Mengting Li, Liuliu Gao, Zuo Wang, Lingkong Zeng, Chen Chen, Jun Wang, Sichan Li, Maochang Liu, Yang Wang
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
ObjectiveThe aim of this study was to develop a population pharmacokinetic model for ceftazidime in critically ill children in the pediatric intensive care unit (PICU) and optimize an appropriate dosing regimen for this population.MethodsWe performed
Externí odkaz:
https://doaj.org/article/42ca941e56004d71bcbaa51059b40c20
Autor:
Paul Thoueille, Susana Alves Saldanha, Fabian Schaller, Eva Choong, François Veuve, Aline Munting, Matthias Cavassini, Dominique Braun, Huldrych F. Günthard, Jessy J. Duran Ramirez, Bernard Surial, Hansjakob Furrer, Andri Rauch, Pilar Ustero, Alexandra Calmy, Marcel Stöckle, Caroline Di Benedetto, Enos Bernasconi, Patrick Schmid, Catia Marzolini, François R. Girardin, Thierry Buclin, Laurent A. Decosterd, Monia Guidi
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe pharmacokinetics of long-acting rilpivirine has mostly been studied in clinical trials, which do not fully address the uncertainties that arise in routine clinical situations.Aims and methodsOur population analysis aims to establish per
Externí odkaz:
https://doaj.org/article/58665483a2d948d0a939985937ee8dc8
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 5, Pp n/a-n/a (2024)
Abstract When planning pediatric clinical trials, optimizing the sample size of neonates/infants is essential because it is difficult to enroll these subjects. In this simulation study, we evaluated the sample size of neonates/infants using a model
Externí odkaz:
https://doaj.org/article/14aaca4b0f53435dbcc0f44dcb2cd942